XOMA Royalty plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s).
We have an expansive portfolio of licenses that provides us the right to future potential royalty and milestone payments. The drug candidate assets underlying the licenses are being developed by others.
We are actively acquiring the rights to future potential milestone and royalty payments to pre-commercial therapeutic assets being developed by pharmaceutical and biotech companies.
We use a portfolio approach to acquire new royalty assets, thereby mitigating single-asset binary exposure, and we operate under a capital-efficient structure to strive to deliver shareholder value.
DOWNLOAD NOW »
April 16, 2021
Non-Dilutive, Non-Recourse Financing Backed by VABYSMO® Royalties
December 19, 2023
October 7, 2021
See the latest Iscalimab update from the Novartis December R&D Day
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
